A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP

Inclusion Criteria:

• Meets criteria for CIDP based on EAN/PNS Task Force CIDP guidelines, second revision (2021)

• Has either typical CIDP or 1 of the following CIDP variants: motor CIDP (includingmotor-predominant CIDP), multifocal CIDP (also known as Lewis-Sumner syndrome),focal CIDP, or distal CIDP

• Has residual disability and active disease

• Has not received previous treatment for CIDP; or has stopped receiving CIDPtreatment; or is receiving CIDP treatment (pulsed or oral corticosteroids,immunoglobulins, PLEX, or FcRn inhibitors)

• Participants already receiving CIDP treatment will have to discontinue their CIDPtreatment before first IMP administration and must be willing to switch to the studyIMP

Exclusion Criteria:

• Meets the criteria for possible CIDP based on EAN/PNS Task Force CIDP guidelines,second revision (2021)

• Sensory CIDP (including sensory-predominant CIDP)

• Polyneuropathy of other causes

• Clinical diagnosis of systemic lupus erythematosus (SLE)

• Use of other long-acting immunomodulatory treatment or prior treatment (at any time)with total lymphoid irradiation or bone marrow transplantation